Randomized trial · people

Tirzepatide: HbA1c fell 2.1% vs 1.1% with insulin lispro in SURPASS-6

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For people with type 2 diabetes already on basal insulin, this trial found adding tirzepatide lowered HbA1c and weight more than mealtime insulin, with fewer low blood sugar events, while gut symptoms were its most common side effect.

Kind
Randomized trial
Studied in
People
Number studied
1428
Published
2023
Journal
JAMA

What they tested

The team tested whether weekly tirzepatide works at least as well as mealtime insulin lispro when added to insulin glargine in people with type 2 diabetes whose blood sugar was not controlled on basal insulin.

How the study was done

An open-label, randomized phase 3b trial of 1428 adults with type 2 diabetes who were already using basal insulin, run at 135 sites across 15 countries. On top of insulin glargine, each person got weekly tirzepatide shots (5 mg, 10 mg or 15 mg arms) or insulin lispro 3 times a day for 52 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 52, HbA1c (a 3-month average of blood sugar) changed by -2.1% with tirzepatide (all doses pooled) and -1.1% with insulin lispro, reaching 6.7% vs 7.7%, an estimated difference of -0.98%; tirzepatide was both noninferior and superior. Body weight changed by -9.0 kg with tirzepatide and 3.2 kg with insulin lispro. An HbA1c under 7.0% was reached by 68% on tirzepatide and 36% on insulin lispro. Low blood sugar events (under 54 mg/dL or severe) ran at 0.4 per patient-year with tirzepatide and 4.4 with insulin lispro, while the most common tirzepatide side effects were mild to moderate gut symptoms such as nausea in 14%-26%.

What it doesn’t show

The trial was open-label, so participants and staff knew which treatment was given. It lasted 52 weeks and only included adults already on basal insulin, compared against mealtime insulin rather than placebo.

The paper

Rosenstock et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo